Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Quick Stats
Jun 23, 202661.4
AI Score
BUY2.07
Volume Ratio
Aug 05, 2026
Next Earnings
13
+ve Days (30d)
14
-ve Days (30d)
ABUS Stock Summary
Last updated Jun 23, 2026
ABUS is currently trading at $4.45, positioned above its 200-day moving average of $4.42, indicating a long-term uptrend. The stock has a 52-week range of $3.04 to $5.1.
Technical Analysis: The 50-day moving average stands at $4.37, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 53.761, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.132, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates ABUS at 61.4/100 with a BUY recommendation.
ABUS (Arbutus Biopharma Corporation Common Stock) Indicators
Last updated Jun 23, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 53.761 |
| CMF (20) | -0.132 |
| ROC (10) | 4.953 |
| ADX (14) | 15.023 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 0.023 |
| AROONOSC (14) | 42.857 |
| WILLAMS %R (14) | -46.495 |
| MFI (14) | 72.883 |
ABUS Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
ABUS Price vs Max Options Open Interest
ABUS Max Change In Options Open Interest
ABUS Options - Sort by Max open Interest (near term)
23rd June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ABUS Daily Out of Money Options - Sort by Max open Interest (near term)
23rd June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ABUS Daily In the Money Options - Sort by Max open Interest (near term)
23rd June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ABUS Most Active Options by Volume(near term)
23rd June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Arbutus Biopharma Corporation Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
ABUS Moving Averages Analysis
Arbutus Biopharma Corporation Common Stock has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Jun 23, 2026
Arbutus Biopharma Corporation Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jun 23, 2026
ABUS (Arbutus Biopharma Corporation Common Stock) Simple Moving Averages
Moving Averages are last updated Jun 23, 2026
| Days | MA |
|---|---|
| 10 | 4.36 |
| 20 | 4.4 |
| 30 | 4.37 |
| 50 | 4.37 |
| 100 | 4.36 |
| 200 | 4.42 |
ABUS Fundamental Analysis
| P/E (Forward) | 10.2459 |
| P/E (Trailing) | 5.4398 |
| Market Cap ($) | 891.9 million |
| Earnings/Share ($) | 0.83 |
| Net Proft Margin (%) | 0.8395 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.219 |
| EPS Estimate Next Year ($) | -0.124 |
| WallStreet Target Price ($) | 5.068 |
| Most Recent Quarter |